Fermenta Biotech Limited has scheduled its 74th Annual General Meeting (AGM) for August 11, 2026, to transact business including the adoption of financial statements for the year ended March 31, 2026. The Board of Directors has recommended a final dividend of ₹3.75 per equity share, amounting to 75% of the face value of ₹5 each, subject to shareholder approval. The meeting will be held through Video Conferencing and Other Audio-Visual Means (VC/OAVM) at 3:00 p.m. IST.

The dividend, if approved, will be paid to members whose names appear in the Register of Members as on the record date of Wednesday, August 05, 2026. Payments are scheduled to be made on or before Friday, August 21, 2026, via electronic transfer. The company has notified shareholders that dividend amounts remaining unpaid or unclaimed for seven consecutive years will be transferred to the Investor Education and Protection Fund (IEPF).

Special Business Agenda

Shareholders will consider the re-appointment of Ms. Rajeshwari Datla as a Non-Executive Director. Ms. Datla, who is 76 years old, retires by rotation at this meeting and is eligible for re-appointment. Pursuant to SEBI regulations, her continuation beyond the age of 75 requires approval via a special resolution. She has been associated with the company since 2005 and currently serves on the Nomination and Remuneration Committee and the Corporate Social Responsibility Committee.

The AGM will also seek ratification for the remuneration of the Cost Auditor. The Board has proposed paying ₹2,75,000 plus applicable taxes and out-of-pocket expenses to M/s Joshi Apte & Associates, Cost Accountants, for conducting the cost audit for the financial year ending March 31, 2027.

Related Party Transactions

A special resolution will be put to vote regarding material related party transactions with Fermenta USA LLC (FUSA), a step-down subsidiary of the company. Shareholders are being asked to approve entering into transactions with FUSA for the sale of products up to an aggregate value of ₹100 crore. The approval is valid until the date of the next AGM in 2027. In the previous financial year (2025-2026), transactions with FUSA amounted to ₹21,75,60,039.06.

Additionally, the company seeks approval to pay commission to Non-Executive Directors, including Independent Directors, up to 1% of the net profits for the financial year 2025-26. This commission is proposed to be in addition to sitting fees and meeting expense reimbursements.

Voting and Participation

Remote e-voting will commence on Saturday, August 08, 2026, at 9:00 a.m. IST and conclude on Monday, August 10, 2026, at 5:00 p.m. IST. Members holding shares as on the record date of August 05, 2026, are eligible to vote. Mr. V. N. Deodhar, Proprietor of V. N. Deodhar & Co., has been appointed as the Scrutinizer for the voting process.

Fermenta Biotech has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 to BSE Limited. The disclosure forms part of the company's Annual Report 2025-26 and outlines its adherence to the National Guidelines for Responsible Business Conduct issued by the Ministry of Corporate Affairs. The report highlights that exports accounted for 58% of the company's total turnover in FY 2025-26.

The company operates four plants and one office nationally, serving approximately 20 states and exporting to around 60 countries. Its primary business activities include the manufacturing of Active Pharmaceutical Ingredients, Aqua CHL, Biotechnology, and Nutraceutical products, which constituted 96.4% of the entity's turnover. Vitamin D3 products were the largest contributor, accounting for 87% of the total turnover.

Employee and Workforce Statistics

As of March 31, 2026, Fermenta Biotech employed a total of 891 individuals, comprising 563 employees and 328 workers. The workforce included 535 permanent employees and 95 permanent workers. Women represented 7.28% of the total employee strength and 1.83% of the total worker strength. The company reported that one differently-abled employee was on its rolls.

The Board of Directors comprised nine members, with three women directors representing 33.33% of the board. Key Management Personnel included six members, with one woman holding the position of Executive Director.

Financial and Operational Metrics

The report disclosed a paid-up capital of ₹14,71,54,935. For Corporate Social Responsibility (CSR) purposes, the company reported a turnover of ₹43,053.17 Lakhs and a net worth of ₹37,995.23 Lakhs for the standalone financial year 2024-25. The company confirmed that CSR is applicable under section 135 of the Companies Act, 2013.

Governance and Compliance

The company stated that all policies required by statute have been approved by the Board of Directors. Principle 7 of the National Guidelines on Responsible Business Conduct, regarding influencing public and regulatory policy, was marked as not applicable to the company. Fermenta Biotech holds various certifications including EU-GMP, USFDA, WHO-GMP, ISO 9001, ISO 14001, and ISO 45001.

Regarding grievances, the company reported three complaints from shareholders and 12 from customers in FY 2025-26, all of which were resolved. No complaints were pending resolution at the close of the year. The company also disclosed receiving a GST demand order amounting to ₹1,35,64,986, against which it has preferred an appeal and paid a pre-deposit of ₹13,56,500.